HealthEquity

HQY

Market cap $7.32B

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

HealthEquity remains a 'buy' despite a 10.2% drop after 2027 guidance disappointed the market. HQY's core HSA business continues robust account and asset growth, driving consistent revenue and profit expansion. Management projects 2027 revenue of $1.38–$1.41 billion and EBITDA margins of 43.8–44.3%, supporting a bullish outlook.

HealthEquity, Inc. (HQY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

HQY rides on strong HSA growth, AI-driven efficiency gains and solid Q3 results, though data security threats remain a key risk.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

HealthEquity (HQY) possesses solid growth attributes, which could help it handily outperform the market.

HealthEquity (HQY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

HQY stock gains post Q3 results as earnings and revenue top estimates, supported by rising HSAs and stronger margins.

HealthEquity, Inc. (HQY) Q3 2026 Earnings Call Transcript